Home » Stocks » Neoleukin Therapeutics

Neoleukin Therapeutics, Inc. (NLTX)

Stock Price: $11.99 USD 0.39 (3.36%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $12.25 +0.26 (2.17%) Aug 12, 4:29 PM

Stock Price Chart

Key Info

Market Cap 500.55M
Revenue (ttm) n/a
Net Income (ttm) -75.88M
Shares Out 38.49M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $11.99
Previous Close $11.60
Change ($) 0.39
Change (%) 3.36%
Day's Open 11.65
Day's Range 11.48 - 12.03
Day's Volume 240,464
52-Week Range 2.53 - 18.13

More Stats

Market Cap 500.55M
Enterprise Value 372.06M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.49M
Float 20.34M
EPS (basic) -2.5
EPS (diluted) -2.74
FCF / Share -0.41
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.36M
Short Ratio 6.21
Short % of Float 9.84%
Beta -4.54
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.00
Revenue n/a
Operating Income -77.37M
Net Income -75.88M
Free Cash Flow -20.06M
Net Cash 128.49M
Net Cash / Share 3.08
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -17.04%
ROE -72.73%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(83.49% upside)
Current: $11.99
Target: 22.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-25.00------
Operating Income-70.96-32.62-51.12-37.65-21.34-22.38-9.38-7.68
Net Income-69.44-31.59-50.18-37.00-21.86-24.03-8.73-7.71
Shares Outstanding27.0323.5223.4518.8912.648.670.300.30
Earnings Per Share-2.57-1.34-2.14-1.96-1.73-2.75-49.52-40.23
Operating Cash Flow-15.39-31.58-44.72-30.23-20.27-17.49-7.82-7.23
Capital Expenditures-0.88-0.05-0.49-0.71-0.03-0.090.18-0.01
Free Cash Flow-16.27-31.63-45.21-30.94-20.29-17.57-7.64-7.24
Cash & Equivalents14376.9310810374.4839.1013.832.00
Total Debt1.210.02----2.29-
Net Cash / Debt14276.9110810374.4839.1011.542.00
Book Value14272.6798.8914510836.15-65.69-51.10
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neoleukin Therapeutics, Inc.
Country United States
Employees 45
CEO Jonathan G. Drachman

Stock Information

Ticker Symbol NLTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NLTX


Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.